HYPERKALEMIA RISK COMPARISON IN PATIENTS ON VALSARTAN/SACUBITRIL: NORMAL RENAL PROFILE VERSUS ADVANCED CHRONIC KIDNEY DISEASE

Main Article Content

Dr Zukhrif Bashir
Dr Bushra Rashid
Dr Rabia Bashir
Dr Nehan Shakeel
Dr Usman Ali
Dr Ilsa Binte Ayaz

Abstract

Objective: This study aimed to compare the risk of hyperkalemia in patients receiving sacubitril/valsartan therapy, focusing on differences between those with normal renal function and those with advanced chronic kidney disease (CKD).


Methods: A retrospective cohort analysis was conducted on 150 heart failure patients with reduced ejection fraction (HFrEF), divided equally into two groups based on estimated glomerular filtration rate (eGFR): normal renal function (eGFR ≥ 60 mL/min/1.73 m²) and advanced CKD (eGFR < 30 mL/min/1.73 m²). Hyperkalemia incidence, severity, and treatment discontinuation rates were assessed using electronic health records. Statistical analyses included Chi-square tests, Kaplan-Meier curves, and Cox proportional hazards models.


Results: The advanced CKD group exhibited a significantly higher incidence of hyperkalemia (29.3% vs. 10.7%, *p*=0.005), with severe cases (>6.5 mmol/L) occurring exclusively in this cohort. These patients also faced a 3.2-fold increased hazard of hyperkalemia (HR: 3.2, 95% CI: 1.4–7.1) and higher treatment discontinuation rates (12% vs. 2.7%, *p*=0.03).


Conclusion: Sacubitril/valsartan therapy is associated with a markedly elevated risk of hyperkalemia in advanced CKD patients, necessitating rigorous potassium monitoring and careful clinical management in this population.

Downloads

Download data is not yet available.

Article Details

Section

Articles

How to Cite

HYPERKALEMIA RISK COMPARISON IN PATIENTS ON VALSARTAN/SACUBITRIL: NORMAL RENAL PROFILE VERSUS ADVANCED CHRONIC KIDNEY DISEASE. (2025). The Research of Medical Science Review, 3(5), 1163-1167. https://medscireview.net/index.php/Journal/article/view/1597